Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Cardiac Resynchronization Therapy Market Between 2025 And 2029?
The cardiac resynchronization therapy market has experienced substantial expansion in recent years. It is anticipated to increase from $6.29 billion in 2024 to $6.72 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.9%. This historical growth can be attributed to factors such as an expanding geriatric population, a higher incidence of heart failure, increased investments in research and development for CRT device innovation, greater awareness regarding the therapy’s benefits, physician training programs, and the dynamics of the competitive landscape.
The cardiac resynchronization therapy market size is anticipated to experience robust expansion over the next few years, reaching $8.56 billion by 2029 with a compound annual growth rate (CAGR) of 6.2%. This growth throughout the forecast period stems from the escalating prevalence of heart failure and various cardiac disorders, an expanding geriatric population, a higher incidence of cardiovascular diseases, the inherent demand for CRT therapy, ongoing advancements in pacemaker and defibrillator treatments, and rising awareness surrounding CRT therapy. Significant developments projected for this period include the increased adoption of CRT-D devices in preference to traditional pacemakers, the incorporation of advanced technology, a broadening application of CRT therapy, the integration of artificial intelligence, and the embrace of machine learning.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15531&type=smp
Which Major Market Drivers Are Shaping The Future Of The Cardiac Resynchronization Therapy Market?
The rising occurrence of cardiovascular diseases is anticipated to fuel the expansion of the cardiac resynchronization therapy market in the coming years. These illnesses, known as Cardiovascular Diseases (CVD), encompass various conditions affecting the heart and its blood vessels. The increasing prevalence of cardiovascular disease is attributed to several factors, including an aging population, unhealthy lifestyle choices, elevated tobacco consumption, sedentary habits, and inadequate dietary intake. Cardiac resynchronization therapy (CRT) offers assistance for cardiovascular conditions, such as heart failure, by enhancing the synchronized movement of the heart’s contractions through the precise delivery of electrical impulses. For instance, in September 2024, data released by the Minnesota Department of Health, a US-based state health agency, showed that approximately 30% of adults in Minnesota reported experiencing high blood pressure in 2023, affecting nearly 1.4 million individuals. Furthermore, in 2022, hypertensive diseases were identified as the primary or contributing cause of death for 14,225 residents, constituting almost 28% of all fatalities within the state. Consequently, the increasing prevalence of cardiovascular diseases is a key driver for the growth of the cardiac resynchronization therapy market.
What Are The Different Segment Classifications Within The Cardiac Resynchronization Therapy Market?
The cardiac resynchronization therapymarket covered in this report is segmented –
1) By Type: Cardiac Resynchronization Therapy (CRT)-Defibrillator; Cardiac Resynchronization Therapy (CRT)-Pacemaker
2) By Age: Below 44 Years; 45-64 Years; 65-84 Years; Above 85 Years
3) By End-Use: Hospitals; Cardiac Care Centers; Ambulatory Surgical Centers
Subsegments:
1) By Cardiac Resynchronization Therapy (CRT)-Defibrillator: Single-Chamber CRT-D; Dual-Chamber CRT-D; Triple-Chamber CRT-D; Bi-Ventricular CRT-D
2) By Cardiac Resynchronization Therapy (CRT)-Pacemaker: Single-Chamber CRT-P; Dual-Chamber CRT-P; Triple-Chamber CRT-P; Bi-Ventricular CRT-P
What Trends Are Redefining The Cardiac Resynchronization Therapy Market Dynamics?
Companies operating significantly within the cardiac resynchronization therapy market are dedicated to developing implantable devices to improve treatment outcomes for individuals with heart failure. Implantable devices utilized in cardiac resynchronization therapy (CRT) work by coordinating the contractions of the heart’s ventricles, which enhances pumping efficiency and helps manage heart failure symptoms. For instance, in February 2024, MicroPort Scientific Corporation, a medical device company from China, launched the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D), an implantable device, along with the Navigo 4LV left ventricular pacing leads in Japan. This particular device is the first and only CRT hemodynamic sensor designed to automatically optimize patients on a weekly basis, and critically, while the patient is physically active, thus enabling real-life optimization. The SonR algorithm, which has been clinically proven, has demonstrated a 35% reduction in the risk of heart failure hospitalization and will also contribute to ensuring the well-being and safety of the CRT-D patient.
Which Key Market Players Are Investing In Expansion And Innovation Of Cardiac Resynchronization Therapy Market?
Major companies operating in the cardiac resynchronization therapy market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, Lepu Medical Technology (Beijing) Co. Ltd., Integer Holdings Corporation, Merit Medical Systems Inc., LivaNova PLC, MicroPort Scientific Corporation, Sorin Group, Berlin Heart GmbH, EBR Systems Inc., Corvia Medical Inc., Recor Medical, Jarvik Heart Inc., Cardiac Dimensions Inc., Farapulse Inc., Osypka Medical GmbH, Japan Medical Device Corporation, Imricor Medical Systems Inc., Vascular Dynamics Inc., Svelte Medical Systems, Aleva Neurotherapeutics, BioSig Technologies Inc.
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Cardiac Resynchronization Therapy Market Outlook?
North America was the largest region in the cardiac resynchronization therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Cardiac Resynchronization Therapy Market Report:
https://www.thebusinessresearchcompany.com/customise?id=15531&type=smp
Browse Through More Reports Similar to the Global Cardiac Resynchronization Therapy Market 2025, By The Business Research Company
Vitamin D Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report
Tumor Ablation Therapy Devices Global Market Report 2025
Testosterone Replacement Therapy Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model